ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...

For instance, researchers noticed during the pandemic that people who received the BCG vaccine against tuberculosis—which is ...

Researchers show how LGP2 binds viral RNA ends, moves along the strand, and helps MDA5 form filaments that amplify antiviral ...

Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present at AD/PD TM 2026 International Conferen ...

Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air ...

In a comprehensive review published in Research, investigators from Zhongda Hospital, School of Medicine, Southeast University propose an integrative framework centered on EG to explain this shift ...

Sepsis remains a life-threatening syndrome defined by immune dysregulation and organ dysfunction. While neutrophils act as the primary defenders of ...

Sydney, Australia Monday, March 16, 2026, 10:00 Hrs [IST] ...

MiNK Therapeutics collaborates with C-Further to advance PRAME-targeted iNKT cell therapy for paediatric cancer: New York Thursday, March 12, 2026, 10:00 Hrs [IST] MiNK Therapeuti ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across ...